Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% ...

Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript February 3, 2026 Pfizer Inc. beats earnings expectations. Reported ...

Pharmaceutical operations remain central to large-cap healthcare discussions Balance sheet positioning frames institutional comparisons Broader sentiment reflects themes seen in s&p 500 chart Pfizer ...

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline ...

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer (NYSE: PFE) posted fourth-quarter 2025 revenue of about $18 billion, down 1% from the year-ago quarter, and adjusted ...

Pfizer beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $16.65 billion, down 5.9% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...